Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Andrew Lipman (NPI 1780654889)

Field	Value
Entity Type	Individual
Organization	Andrew Lipman
Address	1392 Wood Duck Trl
City	Naples
State	FL
ZIP	34108
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 23, 2006

Payer Source	Total Paid
Medicare	$5.6M
Medicaid	$0

Key Findings

Andrew Lipman is a Medical Oncology Physician based in NAPLES, FL with an NPI enumerated on 2006-01-23 (~20 years ago), indicating long-standing Medicare enrollment and likely established clinical operations in the region. The provider's specialty and tenure align with a sustained oncology practice focused on outpatient infusion and oncology management.

This provider's Medicare footprint is substantial: Total Medicare revenue is $5.6M while there is no Medicaid billing on file, making the practice effectively single-payer (Medicare) in scale and exposure. The absence of any Medicaid billing suggests limited participation in state Medicaid programs or a payer mix concentrated on Medicare beneficiaries and commercial payers.

Revenue is highly concentrated in a few high-cost oncology drugs: J9271 ($2M, 37.0%), J9144 ($1.1M, 20.3%), and J9299 ($824.2K, 15.1%) together account for 72.4% of this provider's total Medicare revenue. This concentration indicates that a small set of infused oncology agents drives the majority of Medicare income for the practice.

The code mix signals a high-throughput infusion/oncology service line: large volumes of immunotherapy and monoclonal antibody administrations (J9271: 47K claims, $43 avg paid/claim; J9144: 29.2K claims, $38 avg paid/claim; J9299: 34.3K claims, $24 avg paid/claim) are complemented by chemotherapy administration codes (96413: 1.2K claims, $103 avg paid/claim) and supportive injectables such as J0897 and J1569. Together these codes point to on-site drug administration capability, repeated treatment cycles, and an operational focus on infusion services rather than only office-based visits.

On competitive standing, this provider is a national outlier on several high-impact codes: J9271 ranks #19 of 1841 providers nationally (99th percentile; extreme outlier) and J9144 ranks #21 of 615 providers nationally (97th percentile; notably above typical national volume), indicating dominant supply or high-volume administration of these agents relative to peers. Additional extreme or notable outlier signals appear for general oncology throughput and evaluation codes (96413 ranks #35 of 7514, 100th percentile; 99214 ranks #654 of 479517, 100th percentile), reinforcing that this provider operates at a scale well above typical national volumes for both drug administration and some E/M services.

Operationally, claim counts suggest sustained, repeat treatments rather than one-off administrations: examples include 47K claims for J9271, 34.3K claims for J9299, 29.2K claims for J9144, and 26.8K claims for J0185, which together imply ongoing treatment regimens and high patient throughput. The presence of many infusion-related CPT/HCPCS codes (96365, 96372, 96375, G0498) alongside E/M codes indicates integrated clinical and infusion workflows that support serial oncology care.

From a utilization and payer-review perspective, the practice's heavy reliance on a few high-revenue oncology drugs and multiple outlier rankings means it will stand out in network analyses, utilization management reviews, and competitive benchmarking. Those patterns are neutral operational flags that recommend closer review for contract negotiations, drug purchasing strategies, and capacity planning, given the concentration of Medicare revenue in J9271/J9144/J9299.

The lack of any Medicaid billing on file is notable: this provider has no recorded Medicaid revenue, which reduces exposure to Medicaid payment rules and reimbursement rates but may limit participation in state Medicaid networks or community safety-net activity. For payers and market analysts, this single-payer Medicare concentration should be considered when assessing network adequacy, population coverage, and competitive positioning in the Florida oncology market.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	47,000	$40	$2M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	29,160	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	34,340	$20	$824.2K
J0897	Injection, denosumab, 1 mg	15,840	$20	$285.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,390	$100	$236.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,890	$40	$211.9K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,620	$30	$124.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,190	$100	$122.6K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	4,160	$20	$95.7K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	8,430	$10	$50.6K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Andrew Lipman — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	210	16,100	$40	$802.7K
J9299	10	70	15,580	$20	$423.9K
J9144	2	80	9,000	$40	$410.6K
J1569	44	130	4,080	$40	$176.2K
J0897	82	1,060	3,290	$20	$106.5K
J1449	12	40	3,560	$30	$99.2K
J1437	55	110	2,700	$20	$59.9K
Q5119	4	40	1,850	$20	$50.1K
J0885	86	240	6,630	$10	$45.6K
96413	5	730	200	$100	$26.1K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Andrew Lipman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Florida Cancer Specialists & Research Institute, LLC	FL	Medical Oncology Physician	$0	$63.5M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Mohammad Suhail	RI	Internal Medicine Physician	$126.3K	$16M
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
Christopher Lobo	FL	Medical Oncology Physician	$6.1M	$0
Syed Zafar	FL	Medical Oncology Physician	$6M	$0
Yusef Haj-darwish	MA	Emergency Medicine Physician	$744K	$5M
Ronald Goodwich	FL	Nuclear Medicine Physician	$5.7M	$0
Steven Newman	FL	Medical Oncology Physician	$5.7M	$0

Nearby Providers

Other providers in the same ZIP code as Andrew Lipman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Physicians Day Surgery Center, LLC	FL	Ambulatory Surgical Clinic/Center	$2.2M	$0
David Greschler	FL	Pain Medicine (Anesthesiology) Physician	$861.6K	$0
Henry Biggs	FL	Adult Reconstructive Orthopaedic Surgery Physician	$703.8K	$0
Mamad Bagheri	FL	MOHS-Micrographic Surgery Physician	$657.6K	$0
Benjamin Ditty	FL	Neurological Surgery Physician	$590.6K	$0
Diane Brzezinski	FL	Internal Medicine Physician	$524.6K	$0
Gregory Rubin	FL	Sports Medicine (Family Medicine) Physician	$477.1K	$0
David White	FL	Internal Medicine Physician	$391.9K	$0
Michael Havig	FL	Sports Medicine (Orthopaedic Surgery) Physician	$388K	$0
Nijal Sheth	FL	Nephrology Physician	$343.7K	$0

Andrew Lipman — Billing Profile & Reimbursement Data

Sign up for Andrew Lipman — Billing Profile & Reimbursement Data policy alerts

Andrew Lipman — Billing Profile & Reimbursement Data

Sign up for Andrew Lipman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References